At this year’s International Liver Congress (ILC)™, by the European Association for the Study of the Liver (EASL), Antaros Medical’s Senior Imaging Director Olof Eriksson and co-authors will present further findings from our liver imaging method study (AM-02), performed as a collaboration between Antaros Medical, Uppsala University and Boehringer Ingelheim. The study investigates the use of a variety of magnetic resonance imaging (MRI) and positron emission tomography (PET) biomarkers in a biopsy proven metabolic dysfunction-associated steatotic liver disease (MASLD; previously called non-alcoholic fatty liver disease or NAFLD) population to distinguish between metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH) and nonalcoholic fatty liver (NAFL) subjects and different stages of liver fibrosis, as well as the repeatability of these imaging biomarkers.
The presented data at the EASL ILC 2022 focus on the use of radiowater perfusion PET of the liver. It shows that radiowater PET has similar value as more established biomarkers to discriminate between NAFLD and NASH, and activity and fibrosis grade. However, radiowater PET has the added benefit to provide mechanistic insights on regional and global liver perfusion in clinical trials.
Find out more at the ILC 2022!
Title: Radiowater perfusion PET of the liver, and its value as a biomarker to discriminate between Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis, and activity and fibrosis grade
Abstract number: FRI047
Authors: Eriksson O, Heurling K, Hockings P, Johansson E, Wanders A, Ahlström H, Johansson L, Vessby J, Rorsman F, Lubberink M
Poster presented Friday, 24 June 2022
More around the AM-02 liver imaging study
The main results from our AM-02 liver imaging method study were recently published in the journal of Magnetic Resonance imaging, further underlying the value of MRI in MASLD. For a deeper insight, find the publication here:
Title: The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis
Authors: Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen H G, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C